Dr. Robert Hancock reports

ASEP MEDICAL HOLDINGS LICENSES ITS ANTI-BIOFILM TECHNOLOGY TO BONDENT GROUP FOR ORAL RINSE DEVELOPMENT AND COMMERCIALIZATION IN CHINA

On Aug. 1, 2025, ASEP Medical Holdings Inc. entered into a patent licensing agreement with Shanghai Bondent Technology Co. Ltd., a leading China-based dental-medical company, to develop and commercialize a new oral rinse incorporating ASEP Medical's patented anti-biofilm peptide technology as the active ingredient.

Under the agreement, Bondent will oversee the development, clinical trials and marketing of an oral rinse in key global dental markets, beginning with China, through its extensive network of dental clinics, distributors and training platforms. In return, ASEP Medical's subsidiary, ABT Innovations Inc., will earn a 10-per-cent royalty on all sales of the oral rinse. Bondent will retain the rights to use the technology in the following territories: the People's Republic of China, Taiwan, Mongolia, North Korea, South Korea, Thailand, Papua New Guinea, Vietnam, Indonesia, the Philippines, Malaysia, the Russian Federation, Singapore, Hong Kong and Macao.

ASEP Medical's proprietary peptides are designed to selectively attack and disrupt bacterial biofilms, the protective communities of microbes that adhere to surfaces and are responsible for an estimated 65 per cent of all infections. Biofilms are notoriously difficult to treat, highly resistant to antibiotics and, to date, have no FDA-approved (U.S. Food and Drug Administration) targeted therapies. Biofilms are the primary cause of dental diseases.

The company holds, through its subsidiary ABT Innovations Inc., an exclusive global licence to this patented peptide technology, developed by world-renowned microbiologist Dr. Robert E.W. Hancock and his team at the University of British Columbia. These peptides have demonstrated potent anti-biofilm and anti-inflammatory activity and are in advanced development for multiple applications, including oral rinses and wound dressings.

"This agreement with Bondent is a major milestone in our strategy to bring truly novel anti-biofilm solutions to large global markets," said Dr. Hancock, chief executive officer of ASEP Medical. "Bondent's strength in dental equipment, services and education, combined with our patented peptide technology, creates a powerful partnership to address chronic oral biofilm infections that current products simply do not resolve. We believe this oral rinse has the potential to set a new standard of care for dentists and their patients worldwide."

The oral rinse is being designed as a next-generation product for the prevention and mitigation of erosive dental biofilm infections that can lead to periodontitis, peri-implantitis and other chronic oral conditions. Previous feasibility work with ASEP Medical's peptide mouthwash has shown promising activity against oral biofilms in preclinical and early clinical settings.

Other news

The company also announces that Timothy Murphy has informed the company's board of directors of his decision to step down as chief operating officer, corporate secretary and a member of the board of directors, effective Oct. 31, 2025.

Mr. Murphy's departure from these roles is part of a strategic transition within the ASEP Medical Holdings group of companies. He will assume a board position with Sepset Biosciences Inc., a subsidiary of ASEP Medical, where he will take on an expanded leadership role to advance the commercialization of SepsetER, Sepset's proprietary and highly anticipated sepsis diagnostic technology, currently in advanced development.

"We sincerely thank Timothy for his leadership and operational contributions to ASEP Medical," said Dr. Hancock. "His deep understanding of licensing, our technology and markets makes him ideally positioned to assist in accelerating the commercialization of SepsetER."

Mr. Murphy expressed his enthusiasm for the transition, stating: "SepsetER has the potential to transform how sepsis is diagnosed and treated. I'm excited to dedicate my focus to bringing the SepsetER technology to market."

The company confirms that the transition was mutually agreed upon and reflects ASEP Medical's commitment to aligning leadership resources with its key strategic priorities in infectious disease diagnostics and therapeutics.

About ASEP Medical Holdings Inc.

ASEP Medical is a standout biotechnology research and development company based in Victoria, B.C., Canada. The company possesses a valuable portfolio of global patents for innovative diagnostic and therapeutic medical technologies. These technologies were developed over the past decade at the University of British Columbia under the guidance of Dr. Hancock, one of the world's foremost microbiologists and the chief executive officer of ASEP. ASEP holds a controlling interest in two private subsidiary companies -- Sepset Biosciences (ASEP's leading product, a sepsis diagnostic technology) and ABT Innovations (specializing in anti-biofilm technology). As the company's patented innovations address unmet medical needs, it presents a unique investment opportunity for both retail and institutional investors. It is also an attractive buyout target for a major global pharmaceutical operator.

We seek Safe Harbor.